Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Community study demonstrates Keppra’s use in various pain types

21.03.2003


New data shows that the antiepileptic drug Keppra (levetiracetam), when used alone and in combination with other treatments, provided relief to more than 90 percent of patients with a range of pain syndromes, from migraine headaches to neck and back pain. The study of 400 patients, conducted by the Statesville Pain Associates of Statesville, N.C., was presented today at the American Pain Society’s 22nd Annual Scientific Meeting.



"To date, studies of Keppra to treat pain have been conducted in small patient populations only. Our study of hundreds of patients showed that Keppra was well tolerated and has the potential to be an effective pain treatment alone or in combination with gabapentin, the current ’gold standard’ for the treatment of neuropathic pain," said Douglas Pritchard, M.D., pain specialist and lead investigator of the study. "As pain specialists, we’re always searching for more treatment options. It’s been encouraging to see this response to treatment in such a wide variety of pain states."

Each year chronic pain affects 70 million Americans, or approximately one in every four people, and contributes to 40 million doctor visits. The burden of pain also results in 515 million lost workdays, and accounts for $100 billion in medical expenses each year.1


Investigators determined that 372 of 400 patients involved in the study responded to Keppra, currently approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults. Keppra was given as a stand-alone treatment or in combination with gabapentin, another antiepileptic drug (AED) used to treat pain, to 400 patients experiencing migraine headaches, neck, back, nerve, diabetic and complex regional pain syndromes.

This retrospective analysis was of 400 patients given Keppra over a six-month period as a stand-alone drug (n=30%) and in combination with gabapentin (n=70%). Five percent of the patients in this study were treated for migraine headaches and the others were treated for various types of pain including, neck pain (20%), back pain (40%), nerve pain (15%), diabetic pain (15%) and complex regional pain syndromes (5%). Keppra was titrated to dosages between 1,000 and 2,000 mg/day, throughout the duration of treatment (one to six months).

Participants also evaluated their own pain using the visual analog scale (VAS), in which pain is evaluated on a scale of 0-10, with 10 signifying the highest degree of pain. Before starting treatment with Keppra, patients rated their pain between 7 and 10, but within five to 10 days, their self-evaluated VAS scores fell to 5 and 6. The patients’ pain relief was also evaluated by a patient global assessment of pain indicating good pain relief as well as improved function and quality of life.

The most common side effects associated with the use of Keppra in this analysis were drowsiness and nausea.


About Statesville Pain Associates
The pain management team at Statesville Pain Associates strives to minimize patients’ pain, restore their ability to function and ultimately enable them to enjoy a better quality of life. Headed by Dr. Douglas Pritchard and Dr. Bobby Kearney, Statesville Pain Associates treats over 800 patients a month using a multidimensional and a multidisciplinary approach.

Jessica Balaban | EurekAlert!
Further information:
http://www.ncps-cpr.com

More articles from Health and Medicine:

nachricht PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>